- Home
- SPRO vs MRDN Comparison
SPRO vs MRDN Comparison
Compare SPRO & MRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRO | MRDN |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 83.7M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SPRO | MRDN |
|---|---|---|
| Price | $1.20 | $14.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 76.2K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $66,802,000.00 | ★ $182,863,373.00 |
| Revenue This Year | N/A | $16.30 |
| Revenue Next Year | $300.00 | $12.32 |
| P/E Ratio | ★ N/A | $79.61 |
| Revenue Growth | ★ 39.24 | 21.01 |
| 52 Week Low | $1.08 | $6.01 |
| 52 Week High | $3.08 | $16.09 |
Technical Indicators
Market Signals| Indicator | SPRO | MRDN |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 52.74 |
| Support Level | $1.10 | $12.66 |
| Resistance Level | $1.28 | $15.22 |
| Average True Range (ATR) | 0.06 | 1.19 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 40.00 | 72.83 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About MRDN Meridian Holdings Inc. Common Stock
Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.